Bringing the technology together
It's not yet enough to declare a trend, but last week's deal between DNX Corp. and Baxter Healthcare Corp. is the third or fourth this year in which a lead company has gathered under one roof disparate pieces of technology in a related disease area, to form a coherent whole.
Nextran, the partnership formed between DNXX and Baxter, combines the organ transplantation programs from both companies, as well as technology previously licensed by Baxter from Cantab Pharmaceuticals plc (CNTBY) and SangStat Medical Corp. (SANG). (See What They Did.)
Baxter said Nextran will address three primary obstacles to transplantation: identifying compatibility between donor organs and recipients, preventing and treating acute organ rejection, and expanding the supply